文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

部分多巴胺D2受体激动剂阿立哌唑与青少年神经性厌食症患者体重增加有关。

The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

作者信息

Frank Guido K W, Shott Megan E, Hagman Jennifer O, Schiel Marissa A, DeGuzman Marisa C, Rossi Brogan

机构信息

Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Department of Neuroscience, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

出版信息

Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.

DOI:10.1002/eat.22704
PMID:28334444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5392387/
Abstract

OBJECTIVE: Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target. METHODS: Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program. RESULTS: The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment. DISCUSSION: The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.

摘要

目的：寻找支持神经性厌食症治疗的药物一直颇具难度。基于神经科学的方法或许有助于此。近期针对患有神经性厌食症的成人和青少年的脑成像研究表明，与多巴胺相关的奖赏回路高度敏感，可能提供一个治疗靶点。 方法：在此，我们对106名患有神经性厌食症的青少年进行了一项回顾性病历审查，其中部分青少年在一个专门的饮食失调项目治疗期间接受了多巴胺D2受体部分激动剂阿立哌唑的治疗。 结果：结果显示，在治疗期间，阿立哌唑治疗与体重指数（BMI）的更大增幅相关。 讨论：多巴胺受体激动剂的使用可能有助于神经性厌食症治疗取得成功，应进一步开展研究。

相似文献

[1]
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

Int J Eat Disord. 2017-4

[2]
Association of Elevated Reward Prediction Error Response With Weight Gain in Adolescent Anorexia Nervosa.

Am J Psychiatry. 2017-6-1

[3]
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.

Eur Arch Psychiatry Clin Neurosci. 2015-10

[4]
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

Expert Opin Investig Drugs. 2003-4

[5]
D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial.

J Clin Psychiatry. 2015-6

[6]
[Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].

Encephale. 2018-12

[7]
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

Expert Opin Investig Drugs. 2007-6

[8]
Association of Brain Reward Learning Response With Harm Avoidance, Weight Gain, and Hypothalamic Effective Connectivity in Adolescent Anorexia Nervosa.

JAMA Psychiatry. 2018-10-1

[9]
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

J Pharmacol Exp Ther. 2002-7

[10]
Weight gained during treatment predicts 6-month body mass index in a large sample of patients with anorexia nervosa using ensemble machine learning.

Int J Eat Disord. 2024-8

引用本文的文献

[1]
Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.

Int J Eat Disord. 2025-7

[2]
Use of atypical antipsychotics in individuals with anorexia nervosa.

Ment Health Clin. 2025-2-3

[3]
Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.

BMC Psychiatry. 2024-11-7

[4]
Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.

Focus (Am Psychiatr Publ). 2024-7

[5]
Wernicke Encephalopathy Caused by Avoidance-Restrictive Food Intake Disorder in a Child: A Case-Based Review.

Diseases. 2024-5-24

[6]
Pharmacological Studies in Eating Disorders: A Historical Review.

Nutrients. 2024-2-22

[7]
Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.

J Eat Disord. 2023-12-6

[8]
Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents.

J Eat Disord. 2023-9-6

[9]
Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.

J Eat Disord. 2023-7-6

[10]
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.

PLoS One. 2023

本文引用的文献

[1]
Association of Elevated Reward Prediction Error Response With Weight Gain in Adolescent Anorexia Nervosa.

Am J Psychiatry. 2017-6-1

[2]
The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

CNS Drugs. 2016-5

[3]
The Perfect Storm - A Bio-Psycho-Social Risk Model for Developing and Maintaining Eating Disorders.

Front Behav Neurosci. 2016-3-10

[4]
Melanocortin 4 Receptor and Dopamine D2 Receptor Expression in Brain Areas Involved in Food Intake.

Endocrinol Metab (Seoul). 2015-12

[5]
Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series.

Int J Eat Disord. 2016-5

[6]
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

CNS Drugs. 2015-9

[7]
Could dopamine agonists aid in drug development for anorexia nervosa?

Front Nutr. 2014-11-3

[8]
Atypical antipsychotics as augmentation therapy in anorexia nervosa.

PLoS One. 2015-4-29

[9]
Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice.

Endocrinology. 2013-1-1

[10]
Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys.

Psychopharmacology (Berl). 2013-9-29

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索